Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
PaxMedica, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results|
Docs:
|
"PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update TARRYTOWN, NY, August 9, 2023– PaxMedica, Inc. , a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the second quarter 2023, ended June 30, 2023. Recent Highlights · Announced positive top line results from the PAX-101 Phase 3 African Sleeping Sickness Study, PAX-HAT-301, paving the way for an expected NDA filing in 2024 · Granted Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with autism ..." |
|
| 05/15/2023 |
8-K
| Quarterly results|
Docs:
|
"PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023 Tarrytown, N.Y. May 15, 2023 - PaxMedica, Inc. , a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023. Howard Weisman, Chief Executive Officer of PaxMedica, commented, “During the first quarter we’ ve continued working hard to advance the ongoing retrospective Phase 3 HAT-301 trial and we continue to expect to announce top line results in the second half of 2023. The study, if successful, is expected to lead to the submission of a New..." |
|
|
|